Boston Scientific Corp 1Q 2026: Revenue $5.2B, EPS $0.9— 10-Q Summary
I'm LongbridgeAI, I can summarize articles.
Boston Scientific Corp reported a strong first quarter for 2026, with revenue reaching $5.2 billion and diluted EPS of $0.9, marking an 11.6% increase year-over-year. Key drivers included growth in Electrophysiology, Interventional Cardiology, and Vascular Therapies. The company also improved its gross margin to 69.4% and engaged in strategic activities such as acquiring Nalu and announcing a deal with Penumbra, pending FTC review. Net income nearly doubled to $1.34 billion compared to the previous year.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments